PTGX
NASDAQProtagonist Therapeutics Inc.
News · 26 weeks61-73%
2025-12-142026-06-07
Mix2990d
- Insider10(34%)
- SEC Filings8(28%)
- Market7(24%)
- Other3(10%)
- Analyst1(3%)
Latest news
25 items- INSIDERDirector Waddill William D. exercised 9,000 shares at a strike of $11.80 and sold $896,760 worth of shares (9,000 units at $99.64) as part of a pre-agreed trading plan (SEC Form 4)4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)
- NEWSProtagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association CongressNEWARK, CA / ACCESS Newswire / June 1, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that four abstracts highlighting rusfertide in polycythemia vera (PV) will be presented at the 2026 European Hematology Association Congress (EHA2026 Congress), taking place June 11-14, 2026, in Stockholm, Sweden. The presentations include analyses from the randomized, controlled Phase 3 VERIFY study, as well as long-term results from the Phase 2 REVIVE and THRIVE open-label extension studies.The accepted abstracts provide additional perspective on the rusfertide clinical program in phlebotomy-dependent PV, including efficacy and safety outcomes across low-risk and hi
- NEWSProtagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026NEWARK, CA / ACCESS Newswire / May 28, 2026 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in two investment bank conferences taking place in June 2026.2026 Jefferies Global Healthcare Conference; New York, NY - June 2-4, 2026Format: Fireside ChatDay/Time: Wednesday, June 3 at 9:55 A.M. ETWebcast: https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/STGS2oumT8ZPxxrEhwVAR5Goldman Sachs 47th Annual Global Healthcare Conference 2026; Miami, FL - June 8-10, 2026Format: Fireside ChatDay/Time: Wednesday, June 10 at 9:20 A.M. ETWebcast: https://event.webcasts.com/start
- ANALYSTWolfe Research initiated coverage on Protagonist Therapeutics with a new price targetWolfe Research initiated coverage of Protagonist Therapeutics with a rating of Outperform and set a new price target of $135.00
- INSIDERAmendment: President and CEO Patel Dinesh V Ph D exercised 75,000 shares at a strike of $21.58 and sold $7,509,000 worth of shares (75,000 units at $100.12) as part of a pre-agreed trading plan (SEC Form 4)4/A - Protagonist Therapeutics, Inc (0001377121) (Issuer)
- INSIDERPresident and CEO Patel Dinesh V Ph D sold $7,509,000 worth of shares (75,000 units at $100.12) and exercised 75,000 shares at a strike of $21.58 (SEC Form 4)4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)
- SECSEC Form 144 filed by Protagonist Therapeutics Inc.144 - Protagonist Therapeutics, Inc (0001377121) (Subject)
- SECSEC Form SCHEDULE 13G filed by Protagonist Therapeutics Inc.SCHEDULE 13G - Protagonist Therapeutics, Inc (0001377121) (Subject)
- INSIDERDirector Giraudo Bryan exercised 36,000 shares at a strike of $6.63 and sold $5,918,880 worth of shares (59,130 units at $100.10), increasing direct ownership by 62% to 12,695 units (SEC Form 4)4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)
- SECSEC Form 144 filed by Protagonist Therapeutics Inc.144 - Protagonist Therapeutics, Inc (0001377121) (Subject)
- SECSEC Form 10-Q filed by Protagonist Therapeutics Inc.10-Q - Protagonist Therapeutics, Inc (0001377121) (Filer)
- SECProtagonist Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Protagonist Therapeutics, Inc (0001377121) (Filer)
- NEWSProtagonist Reports First Quarter 2026 Financial Results and Provides Corporate UpdateICOTYDE™ (icotrokinra) approved by FDA in March for moderate-to-severe plaque psoriasis, triggering a $50 million milestone payment; Protagonist receives tiered royalties of 6% to 10% and is eligible for up to $580 million in future milestone paymentsRusfertide NDA accepted and granted Priority Review by FDA, with a Prescription Drug User Fee Act target action date in the third quarter of 2026Protagonist exercised its rusfertide opt-out right under the Takeda collaboration on April 28, triggering a $200 million opt-out fee payable to the Company; eligible for additional $200 million opt-out and $75 million milestone payments upon NDA approval, sales milestones of up to $775 million and world
- SECSEC Form SCHEDULE 13G filed by Protagonist Therapeutics Inc.SCHEDULE 13G - Protagonist Therapeutics, Inc (0001377121) (Subject)
- SECSEC Form DEFA14A filed by Protagonist Therapeutics Inc.DEFA14A - Protagonist Therapeutics, Inc (0001377121) (Filer)
- SECSEC Form DEF 14A filed by Protagonist Therapeutics Inc.DEF 14A - Protagonist Therapeutics, Inc (0001377121) (Filer)
- NEWSProtagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda CollaborationOpt-out election makes Protagonist eligible for $200 million upon exercise and an additional $200 million upon FDA approval of rusfertide for polycythemia veraApproval would also trigger a $75 million milestone payment, bringing total potential cash tied to the opt-out election and approval to $475 millionProtagonist becomes eligible for up to $975 million in milestone payments and tiered royalties ranging from 14% to 29% on worldwide net sales NEWARK, CA / ACCESS Newswire / April 28, 2026 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that it has exercised its right to opt out of the 50:50 U.S. profit and loss sharing arrangement under its wo
- INSIDERPresident and CEO Patel Dinesh V Ph D gifted 1,460 shares, decreasing direct ownership by 0.28% to 523,478 units (SEC Form 4)4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)
- INSIDERSEC Form 4 filed by Ali Asif4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)
- NEWSProtagonist Therapeutics Reports Granting of Inducement AwardsNEWARK, CA / ACCESS Newswire / April 16, 2026 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today reported that on April 15, 2026, it issued inducement awards to two recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.The new employees received, in the aggregate, options to purchase 55,425 shares of Protagonist Therapeutics common stock and restricted stock units (RSUs) to acquire 14,425 shares of Protagonist Therapeutics common stock. The exercise price of the options is $105
- NEWSProtagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual MeetingOne-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasisResults further support the differentiated profile of ICOTYDE, the first and only IL-23 receptor targeted oral peptideNEWARK, CA / ACCESS Newswire / March 28, 2026 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced new one-year Phase 3 results for ICOTYDE™ (icotrokinra) were presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting. Data from the Phase 3 ICONIC-ADVANCE 1 and 2 and ICONIC-LEAD studies further support the potential of ICOTYDE as a
- INSIDERSEC Form 4 filed by Molina Arturo Md4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)
- INSIDERSEC Form 4 filed by Selick Harold E4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)
- INSIDERSEC Form 4 filed by Ali Asif4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Protagonist Therapeutics Inc.SCHEDULE 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)
PTGX FAQ
7 questionsWhat does Protagonist Therapeutics Inc. do?
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. It is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PTG-200, an oral, interleukin-23 receptor specific antagonist peptide, which is in phase II clinical trial for the treatment of moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7...Where does PTGX stock trade?
Protagonist Therapeutics Inc. (PTGX) is listed on NASDAQ.What sector and industry is PTGX in?
Protagonist Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Protagonist Therapeutics Inc. go public?
Protagonist Therapeutics Inc. (PTGX) completed its IPO in 2016.What are analysts saying about PTGX?
Protagonist Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform on 2026-05-21. Recent price targets cluster around $4700.00.What companies are similar to PTGX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PTGX side-by-side with any of them on Quantisnow.How can I track PTGX on Quantisnow?
Quantisnow aggregates Protagonist Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PTGX to receive live email and push alerts on every new disclosure.